Episealer® implants approved for sale in France

Report this content

Episurf Medical (NASDAQ: EPIS B) today announces that the company’s knee and ankle implants, Episealer® Knee and Episealer® Talus, are now registered and approved for sale in France, as the notifications to the regulatory agency ANSM have been completed.

“We are making progress on our regulatory strategy, and we are continuing with our global commercialisation plans. This is an important step for our coming work in the French market,” says Pål Ryfors, CEO, Episurf Medical.

Episurf Medical has further received regulatory approval for Episealer® Talus in Israel and is expecting the approval for Episealer® Talus in Poland shortly.


For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12.30 CET on August 14, 2020.